Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rein TherapeuticsRNTX -5.90%30 5-Year Yield-on-Cost % is 0.00 as of Jul. 23, 2026. GuruFocus rates RNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 151 Biotechnology companies, Rein Therapeutics ranks worse than 662250.99% on this metric.
Rein Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Rein Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:
RNTX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.73 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Rein Therapeutics (NAS:RNTX) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Rein Therapeutics 5-Year Yield-on-Cost % Related Terms
RNTX vs IBIO, RANI, OSTX: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Rein Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rein Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rein Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Rein Therapeutics's 5-Year Yield-on-Cost % falls into.
Rein Therapeutics 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Rein Therapeutics (RNTX) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Rein Therapeutics and its competitors. According to the industry distribution chart, Rein Therapeutics ranks #999999 out of 151 companies in the Biotechnology industry.
Is Rein Therapeutics' 5-Year Yield-on-Cost % too high?
Rein Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Rein Therapeutics ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rein Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' 5-Year Yield-on-Cost % compare to IBIO and RANI?
According to the Biotechnology industry distribution chart, Rein Therapeutics ranks #999999 out of 151 companies for 5-Year Yield-on-Cost %. This places Rein Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.73, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Rein Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rein Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Rein Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
30GF Score
Get the complete analysis for RNTX
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNTX has been successfully added to your 
